Skip to content

Comparing Intravenous and Intramuscular Magnesium Sulphate for Preventing Seizure Recurrence in Women With Eclampsia

Frequency of Recurrence of Seizures With Intravenous Versus Intramuscular Magnesium Sulphate in Women With Eclampsia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06997575
Enrollment
200
Registered
2025-05-30
Start date
2025-05-13
Completion date
2025-11-12
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eclampsia, Seizures, Pregnancy

Keywords

Magnesium sulphate, eclampsia, Seizures, intramuscular, intravenous

Brief summary

The goal of this clinical study is to learn whether the way we give magnesium sulphate-into a vein (intravenous, IV) versus into a muscle (intramuscular, IM)-affects how often women with eclampsia have repeat seizures. The main question it aims to answer is: 1\. Do women who receive IV magnesium sulphate have fewer recurrent seizures than those who receive IM magnesium sulphate? Researchers will compare two groups of women with eclampsia: one group will receive a bolus and a continuous IV infusion of magnesium sulphate, and the other will receive a combined IV-plus-IM dosing regimen. Participants will: 1. Be women aged 18-45 years diagnosed with eclampsia in the labour room. 2. Have their basic health information (age, gestation, parity, body mass index) recorded 3. Be randomly assigned (by sealed envelope) to receive either the IV regimen (4 g loading dose then 1 g/hour infusion) or the IM regimen (10 g loading dose with 4 g IV plus 6 g IM, then 2.5 g IM every 4 hours). 4. Continue treatment for 24 hours after their last seizure or delivery, whichever is later. 5. Be monitored in hospital for seizure recurrence. 6. Have any repeat seizure treated immediately with an extra IV dose of magnesium sulphate.

Interventions

Infusion of 20% MgSO4 solution

DRUGMagnesium sulphate intramuscular

Intramuscular injections will be instituted in gluteal region.

Sponsors

Nishtar Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Admitted in labor room due to eclampsia (new onset of grand mal seizure activity and/or unexplained coma during pregnancy)

Exclusion criteria

* Patients with intracranial bleeding (on CT-scan) * Already received MgSO4, phenytoin and diazepam before attending the hospital

Design outcomes

Primary

MeasureTime frameDescription
SeizureWithin 48 hours after the last dose of MgSO4Seizure recurrence

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026